18 Analysts Have This to Say About Regeneron Pharmaceuticals
Portfolio Pulse from Benzinga Insights
18 analysts have provided ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) in the last quarter, with an average price target of $874.06, implying an upside from the current price of $802.67. The current average has decreased by 1.41% from the previous average price target of $886.54.
August 16, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have provided a bullish outlook for Regeneron Pharmaceuticals with an average price target of $874.06, indicating potential growth.
The bullish outlook provided by analysts indicates a potential increase in the stock price of Regeneron Pharmaceuticals. The average price target provided is higher than the current price, suggesting that the stock is undervalued and has room for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100